Browsing Faculty of Health Sciences (FHS) by Title
Now showing items 8616-8635 of 10227
-
Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.
(Oxford Academic, 2019-06-05)BACKGROUND: During the 2014 West African Ebola outbreak, Ebola vaccine development was accelerated. The phase 1 VAC52150EBL1003 study was performed to investigate 2-dose heterologous vaccination with Ad26.ZEBOV and ... -
Safety and Immunogenicity of a Candidate HIV-1 Vaccine,MVA.HIVA, Administered to Healthy Gambian Infants Born to HIV-1/2-Uninfected Mothers
(University of Nairobi, 2011-09)Background: The development of a safe and effective HIV-1 vaccine remains a global priority especially in prevention of mother to child transmission of HIV-1 during breastfeeding. Our vaccine platform consists of ... -
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa
(2008)Summary: The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and ... -
Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon.
(University of Nairobi,College of Health Sciences,, 2010)Malaria is still one of the major public health threats in sub-Saharan Africa. An effective vaccine could be a sustainable control measure that can be integrated into existing health infrastructures. The malaria vaccine ... -
Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.
(College of Health Sciences,, 2009-10)BACKGROUND: A Phase Ia trial in European volunteers of the candidate vaccine merozoite surface protein 3 (MSP3), a Plasmodium falciparum blood stage membrane, showed that it induces biologically active antibodies able to ... -
Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa
(University of nairobiCollege of health science, 2010)Abstract BACKGROUND: We conducted a double-blind, randomized, placebo-controlled Phase I study of a recombinant replication-defective adenovirus type 5 (rAd5) vector expressing HIV-1 Gag and Pol from subtype B and Env ... -
Safety issues in voluntary female surgical contraception: peri-operative complications.
(Department of Obstetrics and Gynaecology, College of Health Sciences, University of Nairobi, 1993)PIP: Worldwide, voluntary surgical contraception (VSC) is among the most widely employed of family planning methods. Relatively few vasectomies have been reported in Kenya over the last decade, with VSC in the country ... -
Safety of a nonoxynol-9 vaginal gel in Kenyan prostitutes. A randomized clinical trial
(University of NairobiFaculty of medicineFaculty of medicine, 1997-05)OBJECTIVE: To evaluate the safety and toxicity of once-daily administration of Advantage-24 (Columbia Research Laboratories, Inc., Rockville Centre, NY), a vaginal gel containing 52.5 mg of nonoxynol-9 (N-9), including ... -
Safety Of Thyroidectomy At A Rural District Hospital In Kenya.
(Department of Surgery, 2007)The clinical outcome of thyroidectomy may be influenced by among other things, the experience of the surgeon performing the procedure. Furthermore, auditing of any surgical procedure helps in monitoring the safety of the ... -
Safety, acceptability, and tolerability of 3 topical microbicides among heterosexual Kenyan men.
(2007-04)To compare the acceptability, tolerability, and safety of 3 topical microbicide formulations (62% ethyl alcohol in emollient gel and 0.1% and 0.4% benzalkonium chloride on a sanitary wipe) for use on male genitalia. This ... -
Salicylate poisoning in children: report of three cases
(University of NairobiSchool of Medicine, 2004)To raise clinicians' awareness of chronic (therapeutic) salicylate poisoning as a common cause of admission in paediatric patients presenting to hospital with respiratory distress (a clinical manifestation of metabolic ... -
Salicylates and myocardial toxicity.
(College of health science,University of Nairobi, 1971) -
Salivary Antimicrobial Peptides As Potential Biomarkers Of Periodontal Disease
(University of NairobiSchool of Dental Sciences, 2010-07)Objectives: Using SELDI-TOF-MS we have previously identified putative salivary biomarkers of periodontitis. Some of these identified peaks were predicted to be antimicrobial peptides (AMPs), specifically alpha defensins ... -
Salivary Gland Tumours in Kenya
(Department of Dental Surgery, College of Health Sciences. University of Nairobi,Oral and Maxillofacial Surgeon. Dental School: University of NairobiOral Pathologist Department of Pathology, Kenyatta National Hospital,, 1992-09)Four hundred and seventeen tumours of salivary glands in Kenya were analysed. There is no evidence of higher incidence of salivary tumours than in non-African countries. The pattern of distribution 'differed from that ... -
Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya
(University of Nairobi.Department of Paediatrics and Child Health, Univeristy of Nairobi, Kenya, 2008-07)Humoral immunity, and specifically immunoglobulin A (IgA) that is directed against human immunodeficiency virus (HIV)-1, may contribute to protection against HIV-1 acquisition at mucosal surfaces. HIV-1-specific IgA has ... -
Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya
(Department of Paediatrics, 2008)Humoral immunity, and specifically immunoglobulin A (IgA) that is directed against human immunodeficiency virus (HIV)-1, may contribute to protection against HIV-1 acquisition at mucosal surfaces. HIV-1-specific IgA has ... -
Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya.
(University of NairobiDepartment of Medicine, 2008-07)Humoral immunity, and specifically immunoglobulin A (IgA) that is directed against human immunodeficiency virus (HIV)-1, may contribute to protection against HIV-1 acquisition at mucosal surfaces. HIV-1-specific IgA has ... -
Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya.
(University of NairobiCollege of health science, 2008) -
Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya.
(University of NairobiFaculty of medicine, 2008)Humoral immunity, and specifically immunoglobulin A (IgA) that is directed against human immunodeficiency virus (HIV)-1, may contribute to protection against HIV-1 acquisition at mucosal surfaces. HIV-1-specific IgA has ...
